Atyr PHARMA (ATYR) News Today $3.24 -0.25 (-7.16%) Closing price 04:00 PM EasternExtended Trading$3.26 +0.01 (+0.46%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod FranchiseMarch 26 at 8:00 AM | globenewswire.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest UpdateAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 5,260,000 shares, a growth of 20.9% from the February 13th total of 4,350,000 shares. Approximately 6.5% of the shares of the stock are short sold. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 4.6 days.March 19, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) and Windtree Therapeutics (NASDAQ:WINT) Head-To-Head ReviewMarch 19, 2025 | americanbankingnews.comJane A. Gross Purchases 3,750 Shares of Atyr PHARMA INC (NASDAQ:ATYR) StockAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) Director Jane A. Gross acquired 3,750 shares of Atyr PHARMA stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $4.00 per share, with a total value of $15,000.00. Following the acquisition, the director now directly owns 9,750 shares of the company's stock, valued at approximately $39,000. This trade represents a 62.50 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.March 18, 2025 | marketbeat.comJane A. Gross Buys 3,750 Shares of Atyr PHARMA INC (NASDAQ:ATYR) StockMarch 18, 2025 | insidertrades.comAtyr PHARMA INC (NASDAQ:ATYR) Receives $18.60 Consensus PT from BrokeragesMarch 18, 2025 | americanbankingnews.comAtyr PHARMA's (ATYR) "Buy" Rating Reiterated at HC WainwrightMarch 17, 2025 | americanbankingnews.comATYR PHARMA Earnings Results: $ATYR Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comaTyr Pharma, Inc. (NASDAQ:ATYR) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | msn.comHC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR)HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Friday.March 15, 2025 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from BrokeragesShares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating onMarch 15, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Issues Earnings ResultsAtyr PHARMA (NASDAQ:ATYR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05.March 14, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Announces Quarterly Earnings ResultsAtyr PHARMA (NASDAQ:ATYR - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05.March 14, 2025 | marketbeat.comaTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are AccumulatingMarch 14, 2025 | seekingalpha.comaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate UpdateMarch 14, 2025 | finanznachrichten.deaTyr Pharma (ATYR) Gets a Buy from Piper SandlerMarch 14, 2025 | markets.businessinsider.comaTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | seekingalpha.comaTyr Pharma shares fall as Q4 loss narrowsMarch 13, 2025 | investing.comaTyr Pharma reports Q4 EPS (18c), consensus (23c)March 13, 2025 | markets.businessinsider.comaTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate UpdateMarch 13, 2025 | globenewswire.comaTyr Pharma publishes efzofitimod data in Science Translational MedicineMarch 12, 2025 | msn.comaTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational MedicineMarch 12, 2025 | markets.businessinsider.comaTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational MedicineMarch 12, 2025 | globenewswire.comPiper Sandler Remains a Buy on aTyr Pharma (ATYR)March 7, 2025 | markets.businessinsider.comaTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisMarch 6, 2025 | globenewswire.comAtyr PHARMA (ATYR) Projected to Post Earnings on ThursdayAtyr PHARMA (NASDAQ:ATYR) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=672341)March 6, 2025 | marketbeat.comaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial ResultsMarch 4, 2025 | globenewswire.comaTyr Pharma to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | globenewswire.comLeerink Partnrs Weighs in on Atyr PHARMA FY2024 EarningsAtyr PHARMA INC (NASDAQ:ATYR - Free Report) - Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Atyr PHARMA in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($0.89) foFebruary 21, 2025 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Receives $19.25 Average PT from BrokeragesAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has received an average rating of "Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to tFebruary 21, 2025 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from BrokeragesAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has been assigned a consensus rating of "Buy" from the five research firms that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year target prFebruary 19, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Earns Outperform Rating from Analysts at Leerink PartnersLeerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday. They set an "outperform" rating and a $16.00 price target on the stock.February 19, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Upgraded by Leerink Partnrs to "Strong-Buy" RatingLeerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday.February 19, 2025 | marketbeat.comaTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlookFebruary 17, 2025 | msn.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 8.5% in JanuaryAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,820,000 shares, a growth of 8.5% from the January 15th total of 3,520,000 shares. Currently, 4.7% of the shares of the stock are sold short. Based on an average trading volume of 820,000 shares, the short-interest ratio is currently 4.7 days.February 17, 2025 | marketbeat.comRBC Capital Keeps Their Buy Rating on aTyr Pharma (ATYR)February 14, 2025 | markets.businessinsider.comaTyr Pharma CFO Broadfoot sells $4,740 in stockFebruary 6, 2025 | msn.comAtyr Pharma's general counsel Nancy Denyes sells $3,398 in stockFebruary 6, 2025 | msn.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 25.0% in JanuaryAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,650,000 shares, an increase of 25.0% from the December 31st total of 2,920,000 shares. Approximately 4.5% of the shares of the company are short sold. Based on an average trading volume of 1,060,000 shares, the days-to-cover ratio is presently 3.4 days.January 30, 2025 | marketbeat.comHere's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn SituationJanuary 30, 2025 | finance.yahoo.comaTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International ConferenceJanuary 29, 2025 | globenewswire.comBrokers Set Expectations for Atyr PHARMA FY2025 EarningsAtyr PHARMA INC (NASDAQ:ATYR - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Atyr PHARMA in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($0.January 22, 2025 | marketbeat.comShort Interest in Atyr PHARMA INC (NASDAQ:ATYR) Expands By 25.0%Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,650,000 shares, an increase of 25.0% from the December 15th total of 2,920,000 shares. Currently, 4.5% of the company's shares are sold short. Based on an average daily volume of 1,060,000 shares, the days-to-cover ratio is presently 3.4 days.January 16, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Atyr PHARMA FY2024 EarningsAtyr PHARMA INC (NASDAQ:ATYR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Atyr PHARMA in a report issued on Thursday, January 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($0.91) per shJanuary 13, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor FitzgeraldCantor Fitzgerald initiated coverage on Atyr PHARMA in a research note on Monday. They set an "overweight" rating for the company.January 6, 2025 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Sees Significant Increase in Short InterestAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,920,000 shares, a growth of 34.6% from the November 30th total of 2,170,000 shares. Approximately 3.6% of the company's shares are sold short. Based on an average daily trading volume, of 988,700 shares, the short-interest ratio is currently 3.0 days.December 28, 2024 | marketbeat.comiTeos Therapeutics price target lowered to $19 from $31 at Wells FargoDecember 20, 2024 | finance.yahoo.comaTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%December 19, 2024 | finance.yahoo.comaTyr Pharma appoints Eric Benevich to the company’s BoardDecember 13, 2024 | markets.businessinsider.comaTyr Pharma Announces the Appointment of Eric Benevich to its Board of DirectorsDecember 12, 2024 | globenewswire.com Remove Ads Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address ATYR Media Mentions By Week ATYR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATYR News Sentiment▼0.760.89▲Average Medical News Sentiment ATYR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATYR Articles This Week▼32▲ATYR Articles Average Week Remove Ads Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amphastar Pharmaceuticals News Ardelyx News Evotec News 89bio News Ocular Therapeutix News Structure Therapeutics News Iovance Biotherapeutics News Calliditas Therapeutics AB (publ) News Aurinia Pharmaceuticals News Gyre Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATYR) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATYR Stock Free ATYR Stock Alerts